foselutoclax

Foselutoclax is an investigational small molecule senolytic drug developed for the treatment of age-related eye diseases such as diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (AMD)[1][2][4]. It acts as a potent and selective inhibitor of Bcl-xL (BCL2-like 1), a protein that supports the survival of senescent cells. By inhibiting Bcl-xL, foselutoclax selectively eliminates senescent cells in the retina—cells implicated in disease progression and vision loss[1][4][9]. This mechanism distinguishes it from standard anti-VEGF therapies by targeting cellular senescence rather than vascular growth factors. Foselutoclax is administered via intravitreal injection and has shown potential to improve retinal function and visual acuity in early-phase clinical trials[8].

Other names

foselutoclaxUBX1325UBX-1325UBX 1325BM-962BM962BM 962